SpringWorks Therapeutics, Inc. (SWTX) shares plummeted 5.98% in after-hours trading on Tuesday, following reports that German pharmaceutical giant Merck KGaA is in advanced talks to acquire the U.S. cancer and rare diseases drugmaker. The potential acquisition raised concerns among analysts about the deal's profitability impact on Merck.
While the acquisition could bolster Merck's cancer-treatment pipeline, analysts questioned whether it would be accretive from the outset. Equita analyst Davide Marchesin pointed out that SpringWorks is currently loss-making despite generating over 350 million euros in annual revenue. This has led to doubts about the deal's immediate financial benefit for Merck.
The market's reaction to these profitability concerns has caused SpringWorks Therapeutics' stock to plunge in after-hours trading, reflecting investor uncertainty about the potential acquisition's implications for the company's financial performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。